Antabio Awarded EUR 0.9 million funding from the Occitanie Region to support the Preclinical Development of MEM-ANT3310, Antabio’s Novel Broad-Spectrum Combination Therapy Targeting WHO’s Priority Pathogens

ANT3310 is a novel, potent and specific inhibitor of bacterial Serine Beta-Lactamases (SBLs) which displays excellent inhibitory activity against both KPC and OXA carbapenemases. It will be administered intravenously in conjunction with meropenem, for treating hospital-acquired infections caused by Gram negative pathogens, including those that are carbapenem-resistant, notably carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant A. baumannii (CRAB), which are WHO Priority Pathogens.

ANTABIO Completes € 12.5M Series A

New investors Omnes, BNP Paribas Développement and Sham Innovation Santé invest an additional €5.2M on top of the €7.3M first closing announced in October 2017.